What Praluent Treats: Main Uses and Benefits

The medication is commonly used in clinical scenarios to help with the management of cardiovascular risk and severe cholesterol imbalances. The therapy is relevant for adults with established atherosclerotic cardiovascular disease (ASCVD) who require secondary prevention, and for individuals with primary hyperlipidemia, including both Heterozygous and Homozygous Familial Hypercholesterolemia (HeFH and HoFH). It is also relevant for pediatric patients aged 8 and older with HeFH.

---

The medication is applied across therapeutic domains where additional symptomatic support is needed for the long-term management of cardiovascular events. It is relevant for managing symptoms that interfere with functional stability, particularly the dangerously elevated Low-Density Lipoprotein Cholesterol (LDL-C) levels that standard lipid-lowering therapies may be insufficient to address.

“The therapy plays a role in managing the long-term cardiovascular risk associated with plaque build-up in the arteries.”

This supportive treatment assists with maintaining functional stability when patients experience persistently high cholesterol levels.

Quick Fact: Use in Elevated LDL-C Contexts
Praluent is applied to address symptom clusters that may become intense or disruptive, specifically when the LDL-C cholesterol burden requires additional symptomatic support beyond maximally tolerated standard oral medications.

Regulatory References

1. European Medicines Agency overview on Praluent

Who can and cannot use Praluent?

The eligibility for Praluent (alirocumab) is defined by regulatory agencies based on specific population requirements and exclusions documented in official labeling.

Absolute Non-Eligibility

Praluent is contraindicated and must not be used by patients who have a history of a serious hypersensitivity reaction to the active substance, alirocumab, or to any component of the medication.

Approved Patient Populations

The medicine is approved for use in adults with primary hyperlipidemia, including Heterozygous or Homozygous Familial Hypercholesterolemia (HeFH/HoFH), and those with established atherosclerotic cardiovascular disease (ASCVD). Pediatric use is restricted to children aged 8 years and older who are specifically diagnosed with HeFH. Use is not established for children under 8 years of age or for children with types of hypercholesterolemia other than HeFH.

Conditions Requiring Caution or Restriction

Official labeling advises caution when Praluent is used in patients with severe renal impairment or severe hepatic impairment (Child-Pugh C) because these groups had limited or no representation in clinical studies. Additionally, use is not recommended during pregnancy or the initial period of breastfeeding, as adequate safety data for these life stages are unavailable.

Interactions with other medicines and products

The interaction profile of Praluent (Alirocumab) is based on official statements from regulatory bodies and focuses primarily on its co-administration with other lipid-lowering therapies.

Documented Pharmacokinetic Interactions

Alirocumab's interaction pattern is characterized by a reduced systemic exposure of the drug when used concurrently with certain co-administered medicines. This reduction is due to the co-administered drug increasing the production of the target protein, PCSK9, which results in faster clearance of Alirocumab from the body.

Co-Administered Medicine	Interaction Outcome (Approximate Reduction)
Statins (HMG-CoA Reductase Inhibitors)	Alirocumab exposure is reduced by approximately 40%
Fenofibrate	Alirocumab exposure is reduced by approximately 35%
Ezetimibe	Alirocumab exposure is reduced by approximately 15%

Absence of Anticipated Interactions

As a large biological molecule (monoclonal antibody), Alirocumab is not anticipated to affect the pharmacokinetics of other medicinal products. Regulatory documents state that no effect on Cytochrome P450 (CYP450) enzymes or drug transporter systems is expected. Consequently, no dosage adjustments are typically required for co-administered medicines based on this type of interaction.

Other Interaction-Related Constraints

• Administration Site Separation: Alirocumab must not be co-administered with other injectable medicinal products at the same injection site.
• Food and Supplements: No known interactions with food, alcohol, or herbal products are reported in official prescribing information.
• Population Notes: Regulatory caution is advised when administering Alirocumab to patients with severe renal impairment or severe hepatic impairment, as data in these specific patient groups are limited.

How Praluent Works

Praluent’s active ingredient, Alirocumab, is a monoclonal antibody that operates through a precise, targeted interruption of lipid metabolism regulation. The mechanism begins in the bloodstream, where Alirocumab selectively binds to and neutralizes the enzyme PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9).

This targeted blockade prevents PCSK9 from performing its normal function of binding to and promoting the degradation of the Low-Density Lipoprotein Receptor (LDLR) on the surface of hepatocytes (liver cells). The inhibition of PCSK9 initiates a cellular cascade that protects the LDLR population. This action directly modulates the processes that control receptor availability, resulting in an increased density of functional LDLRs on the liver surface.

The final physiological consequence emerges from this increased LDLR availability. The enhanced receptor population increases the liver’s capacity to capture and remove LDL-C (Low-Density Lipoprotein Cholesterol) from the bloodstream. This systematic enhancement of lipid catabolism results in a reduced concentration of circulating LDL-C.

How Praluent (Alirocumab) is Used in Clinical Practice

Praluent is administered as a subcutaneous injection using a pre-filled pen or syringe, a route intended for chronic, long-term therapeutic plans. The dosage is typically based on two fixed-interval regimens: either once every two weeks (Q2W) or once every four weeks (Q4W), administered independently of meal timing.

Official Dosing and Administration Schedules

The standard starting regimen for most adults is 75 mg Q2W. An alternative starting dose is 300 mg Q4W, which requires administering two consecutive 150 mg injections at two different sites. The maximum recommended dose is 150 mg Q2W, to which the regimen may be adjusted if the initial response is deemed inadequate after four to eight weeks of use. For patients with Homozygous Familial Hypercholesterolemia (HoFH) or those undergoing LDL apheresis, a 150 mg Q2W regimen is typically used.

Contextual Usage Requirements

Administration requires specific preparation steps to ensure procedural consistency. Before injection, the pen or syringe must be allowed to warm naturally to room temperature for 30 to 40 minutes. The injection site—thigh, abdomen, or upper arm—must be rotated with each dose. No dose adjustment is specified for elderly patients or those with mild to moderate renal or hepatic impairment.

Guidance for Missed Doses

If a dose is missed on the Q2W schedule, it should be administered within seven days to maintain the original schedule. If more than seven days have passed, the missed dose is skipped, and the individual waits for the next scheduled dose. For the Q4W schedule, if a dose is delayed by more than seven days, the dose should be administered, and a new 4-week cycle must be established based on that date.

Research Evidence / Overview of Studies for Praluent

This section outlines the structure of the clinical research that has explored Praluent (alirocumab), focusing on the types of studies conducted, the outcomes monitored, and what aspects of the evidence remain uncertain.

---

Evidence for Use in Established Atherosclerotic Cardiovascular Disease (ASCVD)

Research for this indication consists primarily of major, long-term Randomized Controlled Trials (RCTs). These studies examined the administration of Alirocumab in Adults with pre-existing ASCVD who were already receiving background lipid-lowering therapy. The research monitored primary and secondary endpoints, including the occurrence of Major Adverse Cardiovascular Events (MACE)—a composite of serious heart-related events—as well as changes in the LDL-C biomarker.

Studies described patterns observed in the occurrence of MACE events over observation periods of up to approximately four years. Measurements of changes in the LDL-C biomarker from baseline levels were also reported. Findings describe group patterns observed in the studies, not individual outcomes.

---

Evidence for Use in Primary Hyperlipidemia and HeFH

This evidence is drawn from short- to intermediate-term Randomized Controlled Trials (RCTs) involving Adults with primary hyperlipidemia and those with Heterozygous Familial Hypercholesterolemia (HeFH). These studies primarily focused on the surrogate biomarker LDL-C, often measuring the percentage change from baseline over defined time points.

Data show patterns related to shifts in LDL-C levels in the observed populations. Studies reported that varying proportions of the cohorts reached certain pre-set LDL-C goals. Follow-up durations were limited in many of these trials, and therefore, there is limited information for long-term outcomes for patients who do not have established ASCVD.

---

Evidence for Use in Homozygous Familial Hypercholesterolemia (HoFH)

The research for this rare condition, HoFH, primarily consists of short-term Randomized Controlled Trials (RCTs) involving a small patient population. These studies included Adults with HoFH, generally receiving maximal background lipid-lowering therapy, and focused on the change in the LDL-C surrogate biomarker over a short interval, such as 12 weeks.

Studies monitored changes in LDL-C levels from baseline. Due to the rarity of HoFH, the existing studies are constrained by a small sample size, which means that subgroup findings are uncertain. The long-term patterns of LDL-C maintenance are not fully established from these specific trials.

How to Store and Dispose of Praluent (Alirocumab)

The official labeling defines specific storage conditions for this medication, which is supplied as a solution for injection.

Storage Requirements

Condition	Requirement
Primary Temperature	Store unopened pens/syringes in the refrigerator (36 F to 46 F or 2 C to 8 C).
Freezing/Light	Do not freeze. Store in the original outer carton to protect from light.
Room Temperature Limit	If kept at room temperature (leq 77 F or 25 C), use within 30 days, then discard.
Child Safety	Keep out of the sight and reach of children.

Disposal

Used Praluent pens are classified as sharps. They must be placed immediately into an approved, puncture-resistant sharps disposal container.

Disposal of full sharps containers, unused, or expired product must be managed according to local and state regulations; they must not be placed in household trash or flushed down the toilet.